Know Cancer

or
forgot password

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission


Phase 3
55 Years
N/A
Open (Enrolling)
Both
Leukemia, Myeloid, Acute

Thank you

Trial Information

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission


This is an international, multicenter, placebo-controlled, phase 3 study with a
double-blind, randomized, parallel-group design with de novo AML (Acute Myeloid Leukemia) or
AML secondary to prior diagnosis of Myelodysplastic Syndromes (MDS).


Inclusion Criteria:



1. Male or female subjects ≥ 55 years of age

2. Newly diagnosed, confirmed de novo AML or AML Secondary to prior MDS

3. First CR/CRi with induction therapy ± consolidation therapy within 90 days of
achieving CR

4. Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, 2, 3

Exclusion Criteria:

1. AML with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) or molecular evidence of
such translocations

2. Prior bone marrow or stem cell transplantation

3. Candidate for allogeneic bone marrow or stem cell transplant

4. Have achieved CR/CRi following therapy with hypomethylating agents

5. Diagnosis of malignant disease within the previous 12 months

6. Proven Central Nervous System (CNS) leukemia

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival (OS)

Outcome Description:

Number of participants who survive

Outcome Time Frame:

60 months

Safety Issue:

Yes

Principal Investigator

Barry Skikne, MD

Investigator Role:

Study Director

Investigator Affiliation:

Celgene Corporation

Authority:

United States: Food and Drug Administration

Study ID:

CC-486-AML-001

NCT ID:

NCT01757535

Start Date:

December 2012

Completion Date:

February 2018

Related Keywords:

  • Leukemia, Myeloid, Acute
  • Maintenance therapy
  • AML
  • Acute Myeloid Leukemia
  • oral Azacitidine
  • best supportive care
  • complete remission
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location

Washington University School of MedicineSaint Louis, Missouri  63110
New York Medical CollegeValhalla, New York  10595
Winthrop University HospitalMineola, New York  11501
Cancer Centers of the CarolinasGreenville, South Carolina  29605
Rocky Mountain Cancer CentersThornton, Colorado  80260
Duke University Medical CenterDurham, North Carolina  27710
Arizona Oncology AssociatesTucson, Arizona  85712-2254
University of Texas MD Anderson Cancer CenterHouston, Texas  77030
Providence St. Joseph Medical CenterBurbank, California  91505
Sarah Cannon Research InstituteNashville, Tennessee  37203
Kansas City VA Medical CenterKansas City, Missouri  64128
Cancer Care Center of South TexasSan Antonio, Texas  78229
Cancer Center of Central ConnecticutSouthington, Connecticut  
Yakima Valley Memorial Hospital / North Star LodgeYakima, Washington  98902
Innovative Clinical Research Institute, LLCWhittier, California  90603
Vanderbilt University Medical CenterAtlanta, Georgia  31192
New York Presbyterian Hospital - Weill-CornellNew York, New York  10021
Seidman Clinical TrialsCleveland, Ohio  44106